EMB-09

EMB-09 is a humanized, tetravalent bispecific antibody developed using FIT-Ig (Fabs-In-Tandem Immunoglobulin) technology. It targets both the immunosuppressive ligand programmed cell death-ligand 1 (PD-L1; CD274) and the co-stimulatory receptor OX40 (CD134; TNFRSF4). By simultaneously blocking PD-L1 and activating OX40 in a PD-L1–dependent manner, EMB-09 acts as an immune checkpoint inhibitor and T-cell activator, leading to enhanced antitumor immune responses. Preclinical studies have shown that EMB-09 improves antitumor activity compared to anti–PD-L1 monoclonal antibodies alone by activating effector memory T cells and promoting infiltration of stem-like CD8+ T cells into tumors. The drug is being developed for various advanced solid tumors, including melanoma, non-small cell lung cancer, triple negative breast cancer, head and neck squamous cell carcinoma, nasopharyngeal cancer, hepatocellular carcinoma, gastric cancer, endometrial cancer, ovarian cancer, renal cell carcinoma, small cell lung cancer, colorectal cancer and multiple myeloma. It is administered intravenously or parenterally[1][2][3][4][5][7].